Net loss was $76.9 million, or $0.57 per share, for the quarter ended
December 31, 2007, compared to a net loss of $58.4 million, or $0.45 per
share, for the same period in 2006.
Fourth quarter highlights
Highlights of Amylin's fourth quarter include the following:
-- Positive results from a 24-week study of monotherapy, or stand alone,
BYETTA in drug nave patients with type 2 diabetes. The Company plans
for a regulatory submission for a monotherapy indication to the U.S.
Food and Drug Administration, or FDA, in the first half of 2008.
-- Positive results from a 30-week comparator study of exenatide once
weekly injection and BYETTA taken twice daily in patients with type 2
diabetes. The Company anticipates a regulatory submission to the FDA by
the end of the first half of 2009.
-- Positive results from a 24-week proof-of-concept study with the
combination treatment of pramlintide, an analog of human amylin, and
metreleptin, an analog of human leptin in overweight or obese subjects,
validating the Company's novel integrated neurohormonal treatment of
obesity (INTO) strategy. The Company plans for additional clinical
development in 2008, including the initiation of a Phase 2B study.
Year ended December 31, 2007
Total revenue for the year ended December 31, 2007 was $781.0 million. This includes net product sales of $701.5 million, consisting of $636.0 million for BYETTA and $65.5 million for SYMLIN. This compares to total revenue of $510.9 million for the same period in 2006, including net product sales of $474.0 million consisting of $430.2 million for BYETTA and $43.8 million for SYMLIN.
Revenues under collaborative agreements were $79.5 million for the year
ended December 31, 2007, compared to $36.8 million for the same period in
|SOURCE Amylin Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved